The advantages of second best: comment on "Lactobacilli vs antibiotics to prevent urinary tract infections"

Affiliations

Comment

Barbara W Trautner et al. Arch Intern Med. 2012.

. 2012 May 14;172(9):712-4.

doi: 10.1001/archinternmed.2012.1213.

¹ Section of Infectious Diseases, Department of Medicine, Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas, USA. trautner@bcm.edu

No abstract available

Comment on

Lactobacilli vs antibiotics to prevent urinary tract infections: a randomized, double-blind, noninferiority trial in postmenopausal women.
Beerepoot MA, ter Riet G, Nys S, van der Wal WM, de Borgie CA, de Reijke TM, Prins JM, Koeijers J, Verbon A, Stobberingh E, Geerlings SE. Beerepoot MA, et al. Arch Intern Med. 2012 May 14;172(9):704-12. doi: 10.1001/archinternmed.2012.777. Arch Intern Med. 2012. PMID: 22782199 Clinical Trial.

1. Stapleton AE, Au-Yeung M, Hooton TM, et al. Randomized, placebo-controlled phase 2 trial of a Lactobacillus crispatus probiotic given intravaginally for prevention of recurrent urinary tract infection. Clin Infect Dis. 2011;52(10):1212–1217. - PMC - PubMed
1. Beerepoot MAJ, ter Riet G, Nys S, et al. Lactobacilli vs antibiotics to prevent urinary tract infections: a randomized, double-blind, noninferiority trial in postmenopausal women. Arch Intern Med. 2012;172(9):704–712. - PubMed
1. Relman DA. Microbial genomics and infectious diseases. N Engl J Med. 2011;365(4):347–357. - PMC - PubMed
1. Tosh PK, McDonald LC. Infection control in the multidrug-resistant era: tending the human microbiome. Clin Infect Dis. 2012;54(5):707–713. - PubMed
1. Dethlefsen L, Huse S, Sogin ML, Relman DA. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol. 2008;6(11):e280. doi:10.1371/journal.pbio.0060280. - PMC - PubMed